# Precirix NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/precirix

- Industry: Biotechnology
- Headquarters: Brussels, Belgium
- Website: www.precirix.com
- Total disclosed funding: $56M
- Latest round: Series B (Mar 1, 2022)
- Investors on record: 9

## About

Based in Belgium, Precirix NV operates as a biotechnology firm focused on developing precision radiopharmaceuticals aimed at enhancing cancer treatment outcomes through innovative therapies.Founded in 2014, Precirix NV is headquartered in Brussels, Belgium, and specializes in precision radiopharmaceuticals. The company raised EUR 80.000 mn in its Series A funding round on March 16, 2022, led by investors including BioMed Partners, Forbion, and others. This funding targeted the development of their pipeline, encompassing novel radiopharmaceuticals and related technologies. Geert Raes, Jens De Vos, and Matthias D'Huyvetter are the founders of Precirix, while Ruth Devenyns serves as the CEO.Precirix is focused on developing precision radiopharmaceuticals aimed at improving cancer treatment outcomes. The company’s lead product candidate targets Fibroblast Activation Protein (FAP) and utilizes camelid single-domain antibodies (sdAb) labeled with radiometals, currently transitioning into clinical trials. This innovative approach positions Precirix to potentially introduce the first-in-class alpha-emitting targeted radiotherapy specifically for FAP, a pan-tumor target. The company is also engaged in ongoing research involving various isotopes, linker technology, and combination therapies to broaden its product platform. Precirix’s offerings cater to healthcare providers and institutions involved in oncology treatments, with a focus on markets in Europe and North America.Precirix generates revenue through partnerships and collaborations in the biotechnology and pharmaceutical sectors. The company engages in B2B transactions with healthcare institutions and research organizations that require advanced cancer treatment solutions. The flagship product, which targets FAP, represents a significant focus for commercial partnerships, enabling Precirix to align with entities invested in enhancing cancer treatment protocols. In 2023, Precirix reported an EBITDA of EUR -3,978,420.90.Following the EUR 80.000 mn funding raised in March 2022, Precirix intends to utilize these resources for the development and expansion of its pipeline. This includes bringing additional novel radiopharmaceuticals to clinical settings and further developing their platform to generate new product candidates, linkers, and CMC processes. Precirix is also aiming to expand its market presence in Europe and North America, targeting specific oncology markets. The company’s strategic initiatives are designed to enhance its product offerings and support its mission in the oncology sector.

## Funding rounds

- Series B, Mar 1, 2022, $44M — HealthCap, Gimv, BioMed Partners, Novo Holdings, Forbion, Pontifax Venture Capital, Inkef, V-Bio Ventures, Jeito Capital
- Series A, Nov 22, 2018, $12M — HealthCap, Gimv, BioMed Partners, Novo Holdings, Pontifax Venture Capital, V-Bio Ventures

## Investors

- HealthCap — Series A, Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series A, Series B
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A, Series B
- Novo Holdings — Series A, Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A, Series B
- V-Bio Ventures (https://capitalatlas.ai/funds/v-bio-ventures) — Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Inkef (https://capitalatlas.ai/funds/inkef) — Series B
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series B